• 1
    Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA. A dopaminergic mechanism is involvedin the ‘anxiogenic-like’ response induced by chronic amphetamine treatment: A behavioral and neurochemical study. Brain Res. 2001; 909: 179186.
  • 2
    Millan MJ, Brocco M, Papp M et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors. III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J. Pharmacol. Exp. Ther. 2004; 309: 936950.
  • 3
    Steiner H, Fuchs S, Accili D. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety. Physiol. Behav. 1997; 63: 137141.
  • 4
    Mizuki Y, Suetsugi M, Ushijima I, Yamada M. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997; 21: 573590.
  • 5
    Stein DJ, Westenberg HG, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: Serotonergic and dopaminergic neurocircuitry. J. Clin. Psychiatry 2002; 63 (Suppl. 6): 1219.
  • 6
    Schneier FR, Liebowitz MR, Abi-Dargham A et al. Low dopamine D (2) receptor binding potential in social phobia. Am. J. Psychiatry 2000; 157: 457459.
  • 7
    Gu SF. A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1992; 25: 328330 (in Chinese).
  • 8
    Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol. Bull. 2002; 36: 8293.
  • 9
    World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, 1992.
  • 10
    Rickels K, Rynn MA. What is generalized anxiety disorder? J. Clin. Psychiatry 2001; 62 (Suppl. 11): 412.
  • 11
    Tsukamoto T, Asakura M, Tsuneizumi T, Satoh Y, Shinozuka T, Hasegawa K. Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994; 18: 615618.
  • 12
    Cassano GB, Jori MC, AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: A randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 2002; 17: 2732.
  • 13
    Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004; 50: 134143.
  • 14
    Kato K. Response of patients in mixed state of anxiety and depression to low dose sulpiride. Igaku Kenkyu 1993; 63: 1519.
  • 15
    Nathan C. Points of control in inflammation. Nature 2002; 420: 846852.
  • 16
    Lin CH, Hsieh CC, Chen SJ, Wu TC, Chung RL, Tang RB. The diagnostic value of serum interleukins 6 and 8 in children with acute gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 2006; 43: 2529.
  • 17
    Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005; 135: 659678.
  • 18
    Maes M, Song C, Lin A et al. The effects of psychological stress on humans: Increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313318.
  • 19
    Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov. Disord. 2005; 20: 8689.
  • 20
    Hayase T, Yamamoto Y, Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands. Behav. Pharmacol. 2005; 16: 395404.
  • 21
    Stein DJ. Comorbidity in generalized anxiety disorder: Impact and implications. J. Clin. Psychiatry 2001; 62 (Suppl. 11): 2934.
  • 22
    Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R Generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 2004; 51: 355364.
  • 23
    Mennin DS, Heimberg RG, Jack MS. Comorbid generalized anxiety disorder in primary social phobia: Symptom severity, functional impairment, and treatment response. J. Anxiety Disord. 2000; 14: 325343.
  • 24
    Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain. Res. Bull. 2004; 63: 237241.
  • 25
    Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur. J. Pharmacol. 2004; 487: 105111.
  • 26
    Millan MJ, Gobert A, Rivet JM et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: A comparison with citalopram. Eur. J. Neurosci. 2000; 12: 10791095.